Photodynamic therapy of Bowen’s disease

Bowen’s disease is a form of non-invasive (in situ) squamous cell skin cancer localized in the non-genital area. Russian and European clinical guidelines include photodynamic therapy (PDT) in the standard of care for patients with Bowen’s disease. In the present review, the efficacy and safety profi...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Filonenko, V. I. Ivanova-Radkevich
Format: Article
Language:Russian
Published: Non-profit partnership for development of domestic photodynamic therapy and photodiagnosis "Russian Photodynamic Association" 2024-03-01
Series:Biomedical Photonics
Subjects:
Online Access:https://www.pdt-journal.com/jour/article/view/622
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241292235603968
author E. V. Filonenko
V. I. Ivanova-Radkevich
author_facet E. V. Filonenko
V. I. Ivanova-Radkevich
author_sort E. V. Filonenko
collection DOAJ
description Bowen’s disease is a form of non-invasive (in situ) squamous cell skin cancer localized in the non-genital area. Russian and European clinical guidelines include photodynamic therapy (PDT) in the standard of care for patients with Bowen’s disease. In the present review, the efficacy and safety profile of different PDT regimens for Bowen’s disease are analyzed according to the available literature data. PDT can be used to treat large Bowen’s disease lesions localized in areas of the body characterized by severe healing and in cases where surgery is not feasible. Analysis of the results of studies shows that PDT is superior in efficacy and cosmetic results to traditional local treatments such as 5-fluorouracil or cryotherapy. In all analyzed studies in patients with Bowen’s disease, PDT achieved a significant clinical effect. Complete regression of pathologic foci was achieved in 67-100% of patients. In studies evaluating the recurrence rate of Bowen’s disease after PDT, this value ranged from 2-28% with the range of 6-18% in most of the studies. Most often, 5-aminolevulinic acid and its methyl ester are used for PDT in Bowen’s disease. According to some researchers, aminolevulinic acid allows to achieve a more long-term positive clinical effect with a lower incidence of painful reactions during treatment
format Article
id doaj-art-e2617fc7639d460192e76195e941553c
institution Kabale University
issn 2413-9432
language Russian
publishDate 2024-03-01
publisher Non-profit partnership for development of domestic photodynamic therapy and photodiagnosis "Russian Photodynamic Association"
record_format Article
series Biomedical Photonics
spelling doaj-art-e2617fc7639d460192e76195e941553c2025-08-20T04:00:13ZrusNon-profit partnership for development of domestic photodynamic therapy and photodiagnosis "Russian Photodynamic Association"Biomedical Photonics2413-94322024-03-01124222910.24931/2413-9432-2023-12-4-22-29285Photodynamic therapy of Bowen’s diseaseE. V. Filonenko0V. I. Ivanova-Radkevich1P.A. Herzen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of the Russian FederationPeoples’ Friendship University of Russia (RUDN University)Bowen’s disease is a form of non-invasive (in situ) squamous cell skin cancer localized in the non-genital area. Russian and European clinical guidelines include photodynamic therapy (PDT) in the standard of care for patients with Bowen’s disease. In the present review, the efficacy and safety profile of different PDT regimens for Bowen’s disease are analyzed according to the available literature data. PDT can be used to treat large Bowen’s disease lesions localized in areas of the body characterized by severe healing and in cases where surgery is not feasible. Analysis of the results of studies shows that PDT is superior in efficacy and cosmetic results to traditional local treatments such as 5-fluorouracil or cryotherapy. In all analyzed studies in patients with Bowen’s disease, PDT achieved a significant clinical effect. Complete regression of pathologic foci was achieved in 67-100% of patients. In studies evaluating the recurrence rate of Bowen’s disease after PDT, this value ranged from 2-28% with the range of 6-18% in most of the studies. Most often, 5-aminolevulinic acid and its methyl ester are used for PDT in Bowen’s disease. According to some researchers, aminolevulinic acid allows to achieve a more long-term positive clinical effect with a lower incidence of painful reactions during treatmenthttps://www.pdt-journal.com/jour/article/view/622photodynamic therapybowen’s disease5-aminolevulinic acid5-aminolevulinic acid methyl ester
spellingShingle E. V. Filonenko
V. I. Ivanova-Radkevich
Photodynamic therapy of Bowen’s disease
Biomedical Photonics
photodynamic therapy
bowen’s disease
5-aminolevulinic acid
5-aminolevulinic acid methyl ester
title Photodynamic therapy of Bowen’s disease
title_full Photodynamic therapy of Bowen’s disease
title_fullStr Photodynamic therapy of Bowen’s disease
title_full_unstemmed Photodynamic therapy of Bowen’s disease
title_short Photodynamic therapy of Bowen’s disease
title_sort photodynamic therapy of bowen s disease
topic photodynamic therapy
bowen’s disease
5-aminolevulinic acid
5-aminolevulinic acid methyl ester
url https://www.pdt-journal.com/jour/article/view/622
work_keys_str_mv AT evfilonenko photodynamictherapyofbowensdisease
AT viivanovaradkevich photodynamictherapyofbowensdisease